Business
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical
About this update from Incannex Healthcare Inc.
[{"type":"text","content":"Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms, Representing ResMed NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended December 31, 2024. “Patients with obstructive sleep apnea need new and convenient therapeutic options to manage this serious, chronic and life-threatening disease. We are enthusiastic about the potential for IHL-42X, an oral, once-daily treatment that uniquely targets physiological pathways responsible for the airway obstruction characteristic of OSA. We achieved a key milestone for our OSA program, reporting positive top-line results from a pharmacokinetics (PK) and safety study of IHL-42X, conducted alongside our global Phase 2/3 RePOSA study,” said Joel Latham, Incannex’s President and Chief Executive Officer. “Our new OSA clinical advisory board brings together leading scientific and industry experts, and we are pleased to welcome Dr. Alison Wimms, representing ResMed, a recognized leader in the sleep medicine field. The OSA advisory board will provide valuable insights and guidance for our ongoing global IHL-42X Phase 2/3 RePOSA clinical trial. Looking ahead, we are committed to executing our clinical programs and are energized by the upcoming catalysts, including the top-line readout from the U.S. Phase 2 portion of the IHL-42X trial expected in the first half of 2025.” Operational Highlights Established an IHL-42X OSA Clinical Advisory Board and appointed Alison Wimms, Ph.D. as an advisor, representing ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to Incannex’s new OSA advisory board. The CAB marks an important step in fostering collaboration as we advance our global Phase 2/3 ‘RePOSA’ clinical study in OSA.The RePOSA Global Phase 2/3 clinical trial is progressing well, with strong recruitment and enrollment at the U.S. sites. Building on the positive momentum and continued interest in patient recruitment, the trial design incl...